Study wrapper · #613
Scavenger receptor CD36 mediates inhibition of cholesterol synthesis via activation of the PPARγ/PGC-1α pathway and Insig1/2 expression in hepatocytes.
Editor's note
In HepG2 liver cells, researchers used hexarelin as a CD36 ligand to dissect how CD36 activation reduces cholesterol synthesis. Hexarelin triggered rapid inactivation and degradation of HMG-CoA reductase (the rate-limiting cholesterol-synthesis enzyme) and increased Insig-1/2 expression via PPAR-gamma and PGC-1-alpha signaling, blunting the usual compensatory SREBP-2 response. Because hexarelin is the tool used to activate CD36, the study directly illuminates a growth-hormone-independent metabolic mechanism relevant to hexarelin's reported cholesterol-lowering effects. The work is entirely in a hepatocyte cell line, so it is mechanistic rather than physiological. These are preclinical findings; human data are needed before any clinical conclusions can be drawn.
Plain-language abstract
Using human liver cells grown in the lab, researchers explored how activating a receptor called CD36 lowers cholesterol production. They used hexarelin, a synthetic peptide, as the trigger for CD36. Hexarelin quickly switched off and marked for destruction the key enzyme (HMG-CoA reductase) that the body uses to make cholesterol, and it increased levels of proteins (Insig-1 and Insig-2) that keep cholesterol production in check. Because hexarelin was the tool used to activate CD36, the study helps explain how hexarelin may lower cholesterol through a route separate from growth hormone. This is a preclinical study in isolated liver cells, not animals or people; human research would be needed before drawing clinical conclusions.